OyaGen Appoints Former Assistant U.S. Surgeon General to Board of Directors
ROCHESTER, N.Y. (June 11, 2013)—OyaGen today announced the appointment of Roscoe M. Moore Jr., DVM, Ph.D.,MPH, assistant U.S. surgeon general (retired) to the company’s board of directors.
Mooreserved as a career officer in the U.S. Public Health Service Commissioned Corps, achieving the rank of assistantU.S.surgeon general during three presidential administrations, and was selected as chief veterinary medical officer for the U.S. Public Health Service by Surgeon General C. Everett Koop. Prior to his retirement,Mooreserved in the Immediate Office of the U.S. Secretary for the Department of Health and Human Services and was the primary person responsible for global development support within the Office of the Secretary.Moorehas authored more than 100 publications on a range of public-health issues, including HIV, and served on the board of directors ofFogartyInternationalCenterat the National Institutes of Health (NIH), appointed by theU.S.secretary of health and human services.Mooreis a fellow of theAmericanCollegeof Epidemiology and has been involved in the fight against the HIV epidemic since its beginning.
“We are very gratified that Dr. Moore has agreed to join our board of directors,” OyaGen founder and CEO Dr. Harold Smith said. “Dr. Moore brings in-depth experience to our national and global efforts to control HIV/AIDS and the relationships needed to create a united global effort to bring solutions and an eventual end to this plague. OyaGen has reached a pivotal stage in development of its first-in-class HIV drugs and is drawing increasing attention and support from government agencies that administer efforts to conquer HIV/AIDS. Our association with Dr. Moore will significantly enhance our long-term success in the fight against HIV.”
“I am very happy to be joining OyaGen’s board of directors,”Mooresaid, “I look forward to facilitating the advancement of the company’s exciting therapeutic platform for HIV.”
OyaGen is a small biotechnology company located inRochester,N.Y.It develops preclinical, innovative, patent-protected therapeutics for HIV. The company has developed a robust intellectual portfolio to support its growing pipeline of HIV-drug candidates and proprietary drug targets.
In addition to its investors, OyaGen has received public support for its work from the NIH and the Gates Foundation, as well as other public and private sources.
About OyaGen
OyaGen Inc. is a development-stage biotechnology company located inRochester,N.Y.OyaGen develops first-in-class therapeutics based on its expertise in the use of editing enzymes as therapeutics and/or drug targets. OyaGen’s therapeutic focus is on treatments and cures for viral illnesses, particularly HIV/AIDS.
For more information, please contact Harold C. Smith, founder and CEO/CSO, at hsmith@oyageninc.com or Thomas Fitzgerald,COO, at tfitzgerald@oyageninc.com.
